XenoPort Comeback - 500 Beiträge pro Seite
eröffnet am 19.09.14 19:52:31 von
neuester Beitrag 16.03.15 18:49:29 von
neuester Beitrag 16.03.15 18:49:29 von
Beiträge: 7
ID: 1.199.432
ID: 1.199.432
Aufrufe heute: 0
Gesamt: 2.880
Gesamt: 2.880
Aktive User: 0
ISIN: US98411C1009 · WKN: A0EQ96
7,0700
USD
0,00 %
0,0000 USD
Letzter Kurs 06.07.16 Nasdaq
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 1,0400 | +48,57 | |
| 0,5400 | +38,46 | |
| 5,4000 | +27,06 | |
| 1,9900 | +26,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,3700 | -25,93 | |
| 3,0200 | -27,58 | |
| 28,18 | -32,62 | |
| 3,6400 | -38,62 | |
| 0,5660 | -40,42 |
Feedback
So XNPT ist heiss.
Rechne mit starkem Zuwachs vor allem bei guten news zu XP21279
Rechne mit starkem Zuwachs vor allem bei guten news zu XP21279
Der Gratistipp für 2015 von Banc of lunatics
Kursziel 15.-
Kursziel 15.-
Quelle www.barchart.com
Xenoport provides highlights of HORIZANT prescription trends and update on development for alcohol use disorder
The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013.
The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742.* The current wholesale acquisition cost (WAC) price is $7.69 per tablet.
During the third quarter of 2014, XenoPort increased its field sales force of NeuroHealth Sales (NHS) Specialists from approximately 40 to 65 representatives. The number of prescribed tablets for the 13 weeks ending December 19, 2014 in the territories occupied by the new NHS Specialists was 227,897, an increase of 46% compared to the 13 weeks ending June 27, 2014, which was prior to the addition of the new NHS Specialists.
XenoPort also provided the following update on the development of HORIZANT as a potential treatment for AUD:
In the fourth quarter of 2014, representatives from XenoPort and the National Institutes for Alcohol Abuse and Alcoholism conducted a pre-investigational new drug meeting with the FDA. Based on the meeting, XenoPort believes that the FDA has accepted the NIAAA's design of the proposed pivotal clinical trial of HORIZANT as a potential treatment for AUD. In addition, XenoPort believes that it may be possible for this clinical trial to support a potential supplemental new drug application for HORIZANT if the results from the trial are robust and compelling and if there is additional confirmatory evidence from the literature or other sources to support the findings.
The NIAAA submitted an IND for HORIZANT as a potential treatment for AUD in December 2014 and has indicated that, upon clearance of the IND, the NIAAA's proposed pivotal clinical trial will begin in the first half of 2015 and that the results may be available by the end of 2016.
The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013.
The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742.* The current wholesale acquisition cost (WAC) price is $7.69 per tablet.
During the third quarter of 2014, XenoPort increased its field sales force of NeuroHealth Sales (NHS) Specialists from approximately 40 to 65 representatives. The number of prescribed tablets for the 13 weeks ending December 19, 2014 in the territories occupied by the new NHS Specialists was 227,897, an increase of 46% compared to the 13 weeks ending June 27, 2014, which was prior to the addition of the new NHS Specialists.
XenoPort also provided the following update on the development of HORIZANT as a potential treatment for AUD:
In the fourth quarter of 2014, representatives from XenoPort and the National Institutes for Alcohol Abuse and Alcoholism conducted a pre-investigational new drug meeting with the FDA. Based on the meeting, XenoPort believes that the FDA has accepted the NIAAA's design of the proposed pivotal clinical trial of HORIZANT as a potential treatment for AUD. In addition, XenoPort believes that it may be possible for this clinical trial to support a potential supplemental new drug application for HORIZANT if the results from the trial are robust and compelling and if there is additional confirmatory evidence from the literature or other sources to support the findings.
The NIAAA submitted an IND for HORIZANT as a potential treatment for AUD in December 2014 and has indicated that, upon clearance of the IND, the NIAAA's proposed pivotal clinical trial will begin in the first half of 2015 and that the results may be available by the end of 2016.
Trading Spotlight
Es wird gekauft wie wild. Bald über 10.- 
Mit ein bisschen Geschick geht sie auf 18+...Horizant sei Dank.
Mit ein bisschen Geschick geht sie auf 18+...Horizant sei Dank.
XNPT ist gerade am explodieren....
Insider ?? oder doch nur gute zahlen ??
Insider ?? oder doch nur gute zahlen ??
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| -0,54 | |
| -1,75 | |
| - | |
| -0,70 | |
| +0,41 | |
| +1,36 | |
| +0,05 | |
| +0,03 | |
| -7,72 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 179 | ||
| 120 | ||
| 77 | ||
| 58 | ||
| 57 | ||
| 57 | ||
| 55 | ||
| 51 | ||
| 44 | ||
| 40 |
